Contributor Page
Singh & Associates
 
Email  |  Website  |  Articles
Contact Details
Tel: +91 11 46667000
Fax: +91 11 46667001
E-337, East of Kailash
New Delhi
110065
India
Awards
Contributor Most Read
Contributor Most Read
Contributor Most Read
Contributor Most Read
Contributor Most Read
By Singh & Associates
On July 09, 2018, the DNP+ filed two pre-grant oppositions at the Indian Patent Office against Gilead's patent application for hepatitis C drug under Section 25(1) of the Patent Act, 1970 (the ‘Act').
By Singh Associates
The CHMP's re-examined the negative recommendation for two drugs Dexxience (betrixaban) and Eladynos.
By Singh & Associates
The FDA issued a compounding risk alert to warn health care providers, compounders and patients of the dangers of using the bulk drug substance cesium chloride.
By Singh & Associates
The FDA also granted Fast Track designation, priority review designations, and Orphan Drug designation to TPOXX.
By Singh & Associates
The WHO, OECD and the World Bank have jointly prepared a report titled "Delivering Quality Health Services – a Global Imperative for Universal Health Coverage " which was released on July 05, 2018.
By Singh & Associates
On July 18, 2018, the FAO, the OIE and the WHO together released a survey report on "Monitoring Global Progress on Addressing Antimicrobial Resistance ".
By Singh & Associates
On July 18, 2018, UNAIDS released a report titled "Miles to go—closing gaps, breaking barriers, righting injustices " as a part of global AIDS update report 2018.
By Singh & Associates
On July 05, 2018, the Council of Scientific and Industrial Research - Institute of Microbial Technology, a premier microbial institute under the aegis of the Ministry of Science and Technology, ...
By Singh & Associates
On July 09, 2018, the Delhi Network of Positive People filed two pre-grant oppositions at the Indian Patent Office against Gilead's patent application for hepatitis C drug under Section 25(1) of the Patent Act, 1970.
By Singh & Associates
The Minister of State for the Ministry of Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy, in a written reply to a query from Lok Sabha, has stated that increasing number of misleading advertisements ...
By Manoj Singh, Daizy Chawla, Vineet Arora, Himanshu Chawla, Shashwat Singh
Section 21(6A)(b) of the I&B Code 2016 read with Regulation 16A of I&B (Insolvency Resolution Process for Corporate Persons) Regulations, 2016 provides for the mechanism w.r.t representation of class of financial creditors ...
By Manoj Singh, Daizy Chawla, Vineet Arora, Himanshu Chawla, Shashwat Singh
The NCLAT, while allowing the appeal, observed that the amended Resolution Plan was in consonant with the section 30(2) of the Code, 2016.
By Manoj Singh, Daizy Chawla, Vineet Arora, Himanshu Chawla, Shashwat Singh
The Reliance Communication-Ericsson legal battle, which led the Anil Ambani controlled company to the insolvency court, has been a watershed moment not just for reflecting the state of the telecom sector, ...
By Manoj Singh, Daizy Chawla, Vineet Arora, Himanshu Chawla, Shashwat Singh
The Ministry of Corporate Affairs, Government of India have released the draft with respect to provisions to be introduced as Chapter for Cross Border Insolvency under the present Insolvency and Bankruptcy Code 2016.
By Manoj Singh, Daizy Chawla, Vineet Arora, Himanshu Chawla, Shashwat Singh
Under the I&B Code, an Insolvency Professional (hereinafter referred as 'IP' or 'IRP') plays a vital role during Corporate Insolvency Resolution Process (CIRP).
Contributor's Topics
More...